WASHINGTON (AP) — In the fight against the coronavirus, one key component of the human immune system has hogged the limelight: antibodies.
These Y-shaped proteins have made top news recently because Covid-19 shots don’t produce as many of them that work against the heavily mutated Omicron variant compared to past strains — at least, not without a booster.
Trained by both vaccines and infection, antibodies grab on to the spike protein that studs the surface of the coronavirus, stopping it from penetrating cells and sickening the host.
But while antibodies are rightly celebrated, they’re not the only game in town.
In fact, “there’s a complex and coordinated response that is really beautiful from an evolutionary standpoint,” Harvard immunologist Roger Shapiro explains.
Here are some key points:
Carpet bombers of the innate immune system
In the minutes and hours after the virus first comes calling, signaling proteins send out alarms to recruit the tough-but-dim brutes of the “innate” immune system.
First to the scene are “neutrophils,” which make up 50 to 70 percent of all white cells and are quick to fight, but also to perish.
Others include hungry “macrophages” that snarf down pathogens and spit out key bits to help train their smarter colleagues, menacingly named “Natural Killer” cells and “dendritic” cells that pass on their intel to more elite fighters.
“It’s sort of like carpet bombing the whole area and hopefully you damage the invader as much as possible… at the same time calling into the headquarters to get your SEAL units ready to go,” said John Wherry, an immunologist at the University of Pennsylvania.
B and T cells: intelligence officers and trained assassins
If the invaders aren’t driven off, the “adaptive” immune system comes into play.
A few days into a first infection, “B cells” wise up to the threat and start pumping out antibodies.
Vaccination also trains B cells — mainly inside lymph nodes in our armpits, near the site of injection — to be primed and ready.
Shapiro likened them to intelligence operatives, holding vital information about threats.
The most potent kinds of antibodies, known as “neutralizing,” are like chewing gum sticking to the business end of a key, stopping it from unlocking a door.
There are other, less-heralded antibodies that aren’t as sticky as the neutralizing kind — but still help grab a hold of the virus, dragging it towards immune cells, or calling for help and escalating the overall response.
B cells’ key partners are “T cells,” which can be broadly split into “helpers” and “killers.”
“Killers are like assassins, and they go and attack the cells that have been infected,” said Shapiro — but these assassins also inflict collateral damage for the sake of the greater good.
The helper T cells “are like generals,” added Shapiro, marshaling troops, spurring B cells to up their production and directing their lethal counterparts toward the enemy.
Stopping severe disease
Because of its heavily mutated spike protein, the Omicron variant may more easily slip by neutralizing antibodies conferred by prior infection or vaccination.
The bad news is this makes people more prone to symptomatic infection. But the good news is that T cells aren’t nearly as easily fooled.
T cells have a “periscope” into infected cells, where they can look for the constituent parts of the virus during its replication cycle, said Wherry.
They’re much better at recognizing tell-tale signs of foes they’ve encountered before, even if their clever disguises get them past antibodies.
The killer T cells carry out search-and-destroy missions, poking holes in infected cells, bursting them open, and triggering reactions to bring inflammatory proteins known as “cytokines” to the fight.
Depending on the speed of the response, a vaccinated person with a breakthrough infection might get mild, cold-like symptoms, or moderate, flu-like symptoms — but the chances of severe disease are drastically reduced.
None of this detracts from the case for boosters, which skyrocket the production of all types of antibodies, and also seem to further train B and T cells.
“Omicron is concerning, but the glass is still half-full — it’s not totally going to evade our responses,” Wherry said.
During a global pandemic, one tiny country is producing research that's helping to guide health policy across the world. How effective are COVID-19 vaccines? After the initial two shots, does a third dose help? What about a fourth?
When The Times of Israel began covering COVID-19, we had no idea that our small beat would become such a central part of the global story. Who could have known that Israel would be first at nearly every juncture of the vaccination story - and generate the research that's so urgently needed today?
Our team has covered this story with the rigor and accuracy that characterizes Times of Israel reporting across topics. If it’s important to you that this kind of media organization exists and thrives, I urge you to support our work. Will you join The Times of Israel Community today?
Nathan Jeffay, Health & Science Correspondent
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we come to work every day - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.